Cipla Ltd.

Financial

	Cipla	Dr. Reddy's Lab	Torrent Pharma
Operational Metrics
Pharmaceutical Sector
Number of ANDA's Filed in USA	284.0 .	361.0 .	168.0 .
Number of ANDA's Approved By USFDA	211.0 .	288.0 .	132.0 .
Domestic Sales Growth - YoY	11.6 %	11.1 %	14.1 %
US DMF Filings	2204.0 .	n/a	n/a
R&D as a % of Total Sales	6.3 %	8.5 %	5.1 %
Financials
5 yr Average ROE	12.48 %	14.9 %	20.0 %
5yr average Equity Multiplier	1.31	1.41	2.34
5yr Average Asset Turnover Ratio	0.78	0.77	0.65
5yr Avg Net Profit Margin	12.29 %	14.03 %	13.21 %
Price to Book	3.9	3.39	14.49
P/E	23.06	20.09	57.57
5yr Avg Cash Conversion Cycle	-4.58 Days	64.1 Days	-189.03 Days
Inventory Days	58.34 Days	75.39 Days	54.5 Days
Days Receivable	45.49 Days	99.54 Days	41.38 Days
Days Payable	110.05 Days	102.35 Days	318.84 Days
5yr Average Interest Coverage Ratio	33.93	34.06	5.79
5yr Avg ROCE	17.45 %	19.83 %	23.72 %
5yr Avg Operating Profit Margin	21.56 %	21.19 %	29.52 %
5 yr average Debt to Equity	0.07	0.12	0.83
5yr CAGR Net Profit	21.66 %	22.45 %	10.08 %
5yr Average Return on Assets	9.64 %	10.71 %	8.58 %
Shareholdings
Promoter Holding	29.2 %	26.64 %	68.31 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-4.43 %	-0.08 %	-2.94 %
Change in Mutual Fund Holding (3 Yrs)	6.6 %	-1.23 %	-2.45 %

Business

	Cipla	Dr. Reddy's Lab	Torrent Pharma
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 95.75 New ventures 4.25 Proprietary Products 0 Global Generics 0 0 US Formulations 0 Domestic formulations 0 Contract Manf. 0 Brazil/Latam 0 Germany/Europe 0	Product Wise Break-Up New ventures 0 Brazil/Latam 0 Domestic formulations 0 Proprietary 0.17 Contract Manf. 0 Pharmaceutical 0 US Formulations 0 Pharmaceutical 13.52 Germany/Europe 0 Formulations 86.31	Product Wise Break-Up New ventures 0 Brazil 8.98 Domestic Formulations 42.15 Proprietary Products 0 Contract Manufacturing 6.15 Pharmaceutical 0 US Formulations 20.71 0 Germany 13.15 Global Generics 0 Others 8.86
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Respiratory Systems 37.5 Anti-Infective 14.0 Cardiac Science 11.4 Anti - Diabetes 5.6 Gastro Intestinal 5.4 Urology 4.7 Pain Management 3.8 Derma 3.3 Central Nervous System (CNS) 3.3 Ophthalmology 3.0 Antivirals 0 Gynaec. 0 Vitamins 0 Antineoplast 0 Oncology 0 Others 8.0	-	-
Location Wise Break-Up	Location Wise Break-Up India 42.0 North America 29.0 SAGA 14.0 Europe 12.0 Global API 2.0 Rest of the World 0 Emerging Markets 0 Russia 0 USA 0 Germany 0 Brazil 0 Others 1.0	Location Wise Break-Up Brazil 0 SAGA 0 Rest of the World 0 North America 0 India 17.36 Germany 0 Emerging Markets 0 USA 48.56 Global API 0 Russia 7.99 Europe 0 Others 26.09	Location Wise Break-Up Brazil 11.86 SAGA 0 Rest of the World 0 North America 0 India 52.21 Germany 9.67 Emerging Markets 0 USA 10.21 Global API 0 Russia 0 Europe 0 Others 16.05
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 100.0 New Ventures 0 Proprietary Products 0 0 Global Generics 0	Operating Profit Break-Up Proprietary Products 0.08 New Ventures 0 Pharmaceuticals 0 Pharmaceutical Services and Active Ingredients 5.34 Global Generics 94.57 Others 0.01	-
Asset Break-Up	Asset Break-Up India 46.99 USA 30.03 South Africa 18.71 United States 0 Switzerland 0 Others 4.27	Asset Break-Up USA 2.37 India 80.24 South Africa 0 Switzerland 8.45 USA 0 Others 8.94	Asset Break-Up United States 0 India 96.58 South Africa 0 Switzerland 0 USA 0.32 Others 3.1

Cipla Ltd.

SIGN UP FOR FREE